4-Week TB pill could revolutionize prevention for millions at risk

NCT ID NCT06568484

Recruiting now Prevention Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 16 times

Summary

This study tests whether a 4-week course of the drug bedaquiline can prevent tuberculosis (TB) as well as the standard longer treatments. It includes 2,530 people living with HIV and close contacts of TB patients, who are at high risk. If successful, this shorter regimen could make TB prevention easier and more accessible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

HNSEB (Hospital Nacional Sergio E. Bernales)
NOT_YET_RECRUITING

Lima, Peru

Contact Email: •••••@•••••
Joint Clinical Research Centre
NOT_YET_RECRUITING

Kampala, Uganda

Contact Email: •••••@•••••
Kilimanjaro Clinical Research Institute
RECRUITING

Moshi, Tanzania

Contact Email: •••••@•••••
MU-JHU Care Ltd.
NOT_YET_RECRUITING

Kampala, Uganda

Contact Email: •••••@•••••
Makerere Lung Institute
NOT_YET_RECRUITING

Kampala, Uganda

Contact Email: •••••@•••••
SES Policlinico
NOT_YET_RECRUITING

Lima, Peru

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

TUBERCULOSIS, LATENT